aTyr Pharma (NASDAQ:ATYR) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS

aTyr Pharma (NASDAQ:ATYR) released its quarterly earnings data on Thursday. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04, FiscalAI reports.

aTyr Pharma Trading Down 6.4%

ATYR stock traded down $0.06 during trading on Thursday, hitting $0.90. The company had a trading volume of 1,293,234 shares, compared to its average volume of 2,013,049. The stock has a market cap of $88.42 million, a PE ratio of -1.09 and a beta of 0.55. The business has a 50-day moving average of $0.83 and a 200-day moving average of $1.47. aTyr Pharma has a one year low of $0.64 and a one year high of $7.29.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of aTyr Pharma in a research note on Monday, December 29th. One research analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $25.67.

Institutional Investors Weigh In On aTyr Pharma

Institutional investors have recently modified their holdings of the company. California State Teachers Retirement System acquired a new stake in shares of aTyr Pharma during the second quarter worth $28,000. Legal & General Group Plc bought a new stake in aTyr Pharma during the second quarter valued at $49,000. Prudential Financial Inc. acquired a new stake in aTyr Pharma during the 2nd quarter worth about $63,000. Oxford Asset Management LLP acquired a new stake in aTyr Pharma during the 2nd quarter worth about $70,000. Finally, Creative Planning bought a new position in shares of aTyr Pharma in the 2nd quarter worth about $74,000. 61.72% of the stock is owned by institutional investors.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.